Gabapentin-structure (Gabapentin Capsule 1)
Gabapentin
Product Images NDC 0440-5563
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 0440-5563). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Liberty Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Gabapentin-fig01 (Gabapentin Capsule 2)
This is a graph showing the weekly mean pain scores of a study with a 4-week dose titration period, followed by a 4-week fixed-dose period on either placebo or Gabapentin with 3600 mg/day. The baseline score is at week 1, and the pain scores were observed over eight weeks. The graph shows that Gabapentin resulted in a statistically significant reduction in pain compared to placebo.*
Gabapentin-fig02 (Gabapentin Capsule 3)
The text describes a study with a graph showing the Mean Pain Score over weeks, with a 3-Week Dose Titration Period and a 4-Week Fixed Dose Period. Three different treatments are shown: a placebo, Gabapentin at 1800mg/day, and Gabapentin at 2400mg/day. The study shows statistical significance with p<0.01.*
Gabapentin-fig03 (Gabapentin Capsule 4)
The text describes a figure (Figure 3) showing the proportion of responders with more than 50% reduction in pain score, at endpoint (end of treatment), in two controlled studies of patients with PHN. The studies were conducted with two different doses of a drug (GBP) compared to a placebo (PBO). The asterisks * indicate the level of statistical significance for the difference between the groups (p<0.01 or p<0.001).*
Gabapentin-fig04 (Gabapentin Capsule 5)
This is a graph titled "Responder Rate in Patients Receiving Gabapentin Expressed as a Difference from Placebo by Dose and Study: Adjunctive Therapy Studies in Patients >12 Years of Age with Partial Seizures". The x-axis represents daily dose (mg) with values ranging from 600 to 1800. The y-axis represents the responder rate in patients receiving Gabapentin expressed as a difference from placebo. The graph has multiple lines representing different studies and doses.*
Image (Gabapentin Capsule 6)
This is a medication label for Gabapentin 600mg capsules, generic for the brand name Neurontin. The medication was produced for US government medical facilities only, and commercial use is prohibited. The capsules are white and oblong with a score of 2 on one side. The manufacturer is Exelan Pharmaceuticals in Lawrenceville, GA, and the medication has an expiration date. The label includes space for the doctor's name and date, as well as space for the patient's information.*
Image (Gabapentin Capsule 7)
This is a description of a medication package produced by AIDAREX PHARMACEUTICALS for US government medical facilities. The medication is a generic equivalent of the brand name NEURONTIN with a strength of 800 mg and a quantity of 180 capsules. The white oblong capsules are imprinted with 'W1' and scored '3' on one side, and contain the active ingredient GABAPENTIN, USP 800MG. No additional information about the medication or its usage is available.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
